NCT07182656View on ClinicalTrials.gov

Safety, Tolerability, and PK/PD of CIGB-814 in Chinese Health Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Rheumatoid Arthritis (RA)
Interventions
DRUG

CIGB-814 (single-dose group)

CIGB-814, single ascending dose, SC injection

DRUG

CIGB-814 placebo (single-dose group)

CIGB-814 placebo, single ascending dose, SC injection

DRUG

CIGB-814 (multiple-dose group)

CIGB-814, multiple ascending dose, SC injection

DRUG

CIGB-814 placebo (multiple-dose group)

CIGB-814 placebo, multiple ascending dose, SC injection

Trial Locations (1)

101149

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Yi Fang

OTHER